zocilurtatug pelitecan (ZL-1310)
Small Cell Lung Cancer
Phase 3Active - Global Phase 3 launched Oct 2025
Key Facts
Indication
Small Cell Lung Cancer
Phase
Phase 3
Status
Active - Global Phase 3 launched Oct 2025
Company
About Zai Lab
Zai Lab is a patient-focused, global biopharma founded in 2014 with a mission to bridge scientific innovation from the West with deep market access and development capabilities in Greater China. The company has established itself as a fully integrated organization with eight commercialized products in China and a promising pipeline of internally discovered and in-licensed assets. Its core strategy combines a hybrid business model of strategic partnerships and internal R&D to address significant unmet medical needs across its core therapeutic areas.
View full company profileTherapeutic Areas
Other Small Cell Lung Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| IMX101 | Imunexus Therapeutics | Preclinical |
| LNTH-2503 | Lantheus Medical Imaging | Phase 1 |
| Small Cell Lung Cancer (SCLC) FFPE | The MT Group | N/A - Service |
| Immunomodulator Platform | OmniCyte | Pre-clinical |
| Discovery Program | Disco Pharmaceuticals | Discovery |
| SHR-1316 | Jiangsu Hengrui Medicine | Phase III |
| SCLC Program | Arcellx | Discovery |
| APG-1252 (Pelcitoclax) | Ascentage Pharma Group | Phase 1/2 |